Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Pre-Mkt 01-13 04:48:24 EST

18.38

-0.92

-4.77%

High19.21	Low17.97	Vol1.20M
Open19.13	D1 Closing19.30	Amplitude6.42%
Mkt Cap1.86B	Tradable Cap1.59B	Total Shares101.37M
T/O22.02M	T/O Rate1.38%	Tradable Shares86.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":18.38,"timestamp":1768251600000,"preClose":19.3,"halted":0,"volume":1195374,"delay":0,"floatShares":86361800,"shares":101369235,"eps":-2.967657,"marketStatus":"Pre-Mkt","change":-0.92,"latestTime":"01-13 04:48:24 EST","open":19.13,"high":19.205,"low":17.965,"amount":22022097.875232,"amplitude":0.064249,"askPrice":21.16,"askSize":100,"bidPrice":14.84,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.967657,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768314600000},"marketStatusCode":1,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":18.38,"postHourTrading":{"tag":"盘后","latestPrice":18.3,"preClose":18.38,"latestTime":"19:41 EST","volume":34167,"amount":627981.46,"timestamp":1768264880864},"volumeRatio":0.7857445976245284,"impliedVol":0.838,"impliedVolPercentile":0.532},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"2602178235","title":"Nurix Therapeutics highlights key objectives, milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602178235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602178235?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:37","pubTimestamp":1768221458,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) highlighted the Company’s achievements in 2025 and outlined key objectives and anticipated milestones for 2026. Key highl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-highlights-key-objectives-milestones-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-highlights-key-objectives-milestones-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2602362512","title":"Nurix Therapeutics : Expand Bexobrutideg Into Autoimmune and Inflammatory Indications, Targeting Ind Submission in 2026 With a New Tablet Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602362512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602362512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:16","pubTimestamp":1768220191,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2602514087","title":"Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514087","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514087?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219200,"startTime":"0","endTime":"0","summary":"Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymph","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216702/0/en/Nurix-Therapeutics-Outlines-2026-Goals-and-Objectives-for-Advancing-Bexobrutideg-and-Its-Pipeline-of-Novel-Degrader-Based-Medicines-in-Cancer-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4084","BK4231","BK4139","LU1169590202.USD","BK4585","CEA","LU1169589451.USD","IND","MDCO","BK4008","PK","BK4217","PSA","SITC","BK4023","BK4500","BK4080","BK4533","PD","BK4181","NRIX","BK4218","BK4588"],"gpt_icon":0},{"id":"2601369118","title":"Nurix Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369118","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369118?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:20","pubTimestamp":1767874800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 07:20 ET (12:20 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2601885009","title":"Nurix Therapeutics to Present Corporate Update at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885009","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885009?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:01","pubTimestamp":1767614477,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Inc. will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco. The presentation will be webcast live and available for replay on the company’s website for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbdV6t5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014021.USD","SG9999014005.SGD","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","BK4139","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","NRIX","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014013.SGD"],"gpt_icon":0},{"id":"2592117323","title":"Does New NX-5948 Phase 2 Dose Selection Change The Bull Case For Nurix Therapeutics (NRIX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592117323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592117323?lang=en_us&edition=fundamental","pubTime":"2025-12-20 14:16","pubTimestamp":1766211404,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, Inc. recently presented new clinical data from its ongoing Phase 1a/1b NX-5948-301 trial of bexobrutideg (NX-5948) in relapsed or refractory B-cell malignancies at the 67th American Society of Hematology Annual Meeting, including safety and efficacy findings across multiple dose levels and patient cohorts.\nThe data underpin selection of a 600 mg dose as the recommended Phase 2 level and support Nurix’s pivotal DAYBreak development program under FDA initiatives Project...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-new-nx-5948-phase-2-dose-selection-change-the-bull-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-new-nx-5948-phase-2-dose-selection-change-the-bull-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4086","NX","BK4139","NRIX","LU2065732104.USD"],"gpt_icon":0},{"id":"2592187247","title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592187247","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592187247?lang=en_us&edition=fundamental","pubTime":"2025-12-19 07:08","pubTimestamp":1766099332,"startTime":"0","endTime":"0","summary":"Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL41qDd1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2591933138","title":"Nurix Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2591933138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591933138?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:08","pubTimestamp":1765897680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 10:08 ET (15:08 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2591198892","title":"Nurix Therapeutics (NRIX): Assessing Valuation After a Sharp Multi-Month Share Price Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2591198892","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591198892?lang=en_us&edition=fundamental","pubTime":"2025-12-16 12:34","pubTimestamp":1765859641,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has quietly turned heads with a sharp rebound, with the stock up roughly 49% over the past month and more than doubling in the past 3 months.\nSee our latest analysis for Nurix Therapeutics.\nThat surge has helped claw back some ground after a tougher stretch, with a 30 day share price return of 48.5% and a three year total shareholder return of 70.0% suggesting positive momentum is rebuilding from a still volatile base.\nIf Nurix’s rebound has you rethinking biotech...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2590587762","title":"Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587762?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:29","pubTimestamp":1765373348,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $27.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","NRIX"],"gpt_icon":0},{"id":"2590586090","title":"Nurix Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $31 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2590586090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590586090?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:10","pubTimestamp":1765365029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nAZN4RCRIP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2590164326","title":"Nurix Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590164326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590164326?lang=en_us&edition=fundamental","pubTime":"2025-12-10 03:02","pubTimestamp":1765306920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 14:02 ET (19:02 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2590311390","title":"Nurix Therapeutics Inc : Btig Raises Target Price to $30 From $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590311390?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:45","pubTimestamp":1765262712,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2590368328","title":"BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368328","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368328?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:45","pubTimestamp":1765219558,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, InstacartEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: http","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEE","ALB","JEF","FULC","DYN","COMP","CRH","OMF","XOM","NRIX","AGIO","FANG","BKR","WBD","LEN","TPL","EXE","MMM","SCCO","HUT","USCB","GPCR","RIOT","OCUL","CFLT","APD","APA","COP","FIVE","KYMR","ROK","CVX","EOG","AR","LNG","FCX","INCY","ACLX","WYNN","GM"],"gpt_icon":1},{"id":"2590660352","title":"Nurix Therapeutics Up Over 18%, on Pace for Larget Percent Increase Since June 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590660352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590660352?lang=en_us&edition=fundamental","pubTime":"2025-12-09 00:17","pubTimestamp":1765210620,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, Inc.  is currently at $21.44, up $3.36 or 18.55%. --Would be highest close since Dec. 10, 2024, when it closed at $22.06. --On pace for largest percent increase since June 18, 2024, when it rose 20.6%. --Currently up four consecutive days; up 31.16% over this period. --Longest winning streak since Nov. 24, 2025, when it rose for four straight trading days. --Down 57.26% from its all-time closing high of $50.17 on Jan. 19, 2021. --Up 3.8% from 52 weeks ago , when it closed at $20.66. --Up 160.25% from its 52-week closing low of $8.24 on Sept. 23, 2025. --Traded as high as $22.50; highest intraday level since Dec. 11, 2024, when it hit $22.95. --Up 24.38% at today's intraday high; largest intraday percent increase since April 9, 2024, when it rose as much as 26.88%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2589351532","title":"Nurix Therapeutics Stock Rises on Positive Trial Data for Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2589351532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589351532?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:48","pubTimestamp":1765205280,"startTime":"0","endTime":"0","summary":"Shares of Nurix Therapeutics rose after the company reported positive trial data for a potential treatment for a type of blood cancer.The stock rose 22% to $22.01 on Monday. Shares are up 13% this year.The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenstrm macroglobulinemia patients in a recent trial.The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said.The drug's encouraging efficacy and favorable tolerability support continued development, the company said.Waldenstrm macroglobulinemia is a rare cancer that affects white blood cells.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589359222","title":"Nurix Therapeutics Shares Jump to Near One-Year High After Early Stage Blood Cancer Drug Trial Data, Last up 20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359222?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:32","pubTimestamp":1765204327,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE16A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589451356","title":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2589451356","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589451356?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:07","pubTimestamp":1765202850,"startTime":"0","endTime":"0","summary":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data** Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket** NRIX said 75% of patients demonstrated objective","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589353249","title":"Nurix Therapeutics Shares Jump 16.2% Premarket After Early Stage Cancer Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353249?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589353672","title":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353672","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353672?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:07","pubTimestamp":1765199238,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenstrm Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And ExpositionDec 8 (Reuters","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABJG6V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":0.0509},{"period":"1month","weight":-0.0362},{"period":"3month","weight":1.0022},{"period":"6month","weight":0.4799},{"period":"1year","weight":0.0077},{"period":"ytd","weight":-0.0311}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.058414},{"month":2,"riseRate":0.2,"avgChangeRate":-0.007659},{"month":3,"riseRate":0.2,"avgChangeRate":-0.071924},{"month":4,"riseRate":0.4,"avgChangeRate":-0.043438},{"month":5,"riseRate":0.4,"avgChangeRate":-0.000824},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}